Similarly, NLR and PLR were reported as poor prognostic indicators in patients with stage III/IV non‐small cell lung cancer or hepatocellular carcinoma with PD‐1 inhibitor [17, 18, 19, 20, 21, 22, 23]. Here, PDCD1 is linked to hepatocellular carcinoma.